Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEERA GROVER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1023169489
CMS profile
136769
Location
APPLE VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$269.57

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $269.57 17

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $125.64 10
RedHill Biopharma Inc. $56.11 3
Gilead Sciences, Inc. $34.79 1
ABBVIE INC. $32.16 2
Ferring Pharmaceuticals Inc. $20.87 1

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEERA GROVER

NPI 1023169489 · CMS profile ID 136769

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

APPLE VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023169489?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEERA GROVER, NPI 1023169489, CMS profile ID 136769. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023169489?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NEERA GROVER, NPI 1023169489, CMS profile ID 136769. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023169489?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NEERA GROVER, NPI 1023169489, CMS profile ID 136769, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023169489?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $269.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
RedHill Biopharma Inc. $20.0511/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902972399 CMS
ABBVIE INC. $14.8511/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892695079 CMS
Merck Sharp & Dohme LLC $8.6810/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944229215 CMS
Ferring Pharmaceuticals Inc. $20.8709/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875350163 CMS
Merck Sharp & Dohme LLC $22.2808/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944207171 CMS
RedHill Biopharma Inc. $16.1807/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902958531 CMS
Merck Sharp & Dohme LLC $7.4106/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944173389 CMS
Merck Sharp & Dohme LLC $20.7505/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944149923 CMS
Merck Sharp & Dohme LLC $16.5004/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944142601 CMS
Merck Sharp & Dohme LLC $7.5204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944125441 CMS
ABBVIE INC. $17.3103/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892695077 CMS
Gilead Sciences, Inc. $34.7903/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929516809 CMS
RedHill Biopharma Inc. $19.8803/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902943759 CMS
Merck Sharp & Dohme LLC $11.0403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944322329 CMS
Merck Sharp & Dohme LLC $11.3102/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944102783 CMS
Merck Sharp & Dohme LLC $7.0601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944320155 CMS
Merck Sharp & Dohme LLC $13.0901/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944063901 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $269.22 8
PY2020 $67.05 2
PY2021 $340.98 21
PY2022 $269.57 17
PY2023 $167.33 8
PY2024 $625.50 24
PY2025 $657.26 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $200,027.03 74
PY2024 Principal investigator $100,849.46 51
PY2023 Principal investigator $219,334.14 67
PY2022 Principal investigator $30,141.50 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,800.00 12/11/2025 Covered Recipient Teaching Hospital
The University Of Texas Medical Br.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211557599
Principal investigator 1 Genentech, Inc. $19,500.00 12/11/2025 Covered Recipient Teaching Hospital
The University Of Texas Medical Br.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211557602
Principal investigator 1 Genentech, Inc. $1,391.00 12/11/2025 Covered Recipient Teaching Hospital
The University Of Texas Medical Br.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211557607
Principal investigator 1 Genentech, Inc. $2,500.00 12/11/2025 Covered Recipient Teaching Hospital
The University Of Texas Medical Br.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211557611
Principal investigator 1 Genentech, Inc. $2,028.00 12/11/2025 Covered Recipient Teaching Hospital
The University Of Texas Medical Br.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211557615
Principal investigator 1 SANOFI US SERVICES INC. $4,914.00 12/08/2025 Non-covered Recipient Entity
Om Research Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226123108
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 12/08/2025 Non-covered Recipient Entity
Om Research Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226123113
Principal investigator 1 ABBVIE INC. $2,569.00 12/04/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202526550
Principal investigator 1 F. Hoffmann-La Roche AG $850.00 12/04/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211634681
Principal investigator 1 Genentech, Inc. $850.00 11/25/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634883
Principal investigator 1 Genentech, Inc. $89.60 11/14/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634876
Principal investigator 1 Genentech, Inc. $266.00 11/14/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634880
Principal investigator 1 Genentech, Inc. $119.00 11/14/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634888
Principal investigator 1 Genentech, Inc. $928.20 11/14/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634911
Principal investigator 1 Genentech, Inc. $154.00 11/14/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634915
Principal investigator 1 Genentech, Inc. $77.00 11/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634894
Principal investigator 1 Genentech, Inc. $204.40 11/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634897
Principal investigator 1 Genentech, Inc. $204.40 11/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634902
Principal investigator 1 Genentech, Inc. $77.00 11/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634907
Principal investigator 1 Genentech, Inc. $850.00 10/29/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634864
Principal investigator 1 Genentech, Inc. $2,451.00 10/23/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634856
Principal investigator 1 ABBVIE INC. $2,927.40 10/09/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202515673
Principal investigator 1 ABBVIE INC. $11,174.80 10/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202513453
Principal investigator 1 Genentech, Inc. $2,771.00 10/03/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634868
Principal investigator 1 Genentech, Inc. $2,596.00 09/18/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634800
Principal investigator 1 Genentech, Inc. $400.40 09/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634816
Principal investigator 1 Genentech, Inc. $77.00 09/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634823
Principal investigator 1 ABBVIE INC. $295.40 09/10/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202510456
Principal investigator 1 ABBVIE INC. $396.00 09/05/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202510162
Principal investigator 1 ABBVIE INC. $2,569.00 09/04/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509164
Principal investigator 1 Genentech, Inc. $277.20 08/26/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634812
Principal investigator 1 Genentech, Inc. $77.00 08/26/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634820
Principal investigator 1 Genentech, Inc. $82.60 08/26/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634827
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 08/21/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171777
Principal investigator 1 Janssen Research & Development, LLC $1,150.00 08/21/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171794
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 08/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211634616
Principal investigator 1 F. Hoffmann-La Roche AG $18,300.00 08/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211634670
Principal investigator 1 Genentech, Inc. $1,540.00 08/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634804
Principal investigator 1 Genentech, Inc. $5,796.00 07/31/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634831
Principal investigator 1 ABBVIE INC. $1,683.00 07/30/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202500508
Principal investigator 1 ABBVIE INC. $736.00 07/17/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202498740
Principal investigator 1 Genentech, Inc. $4,837.00 07/17/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634808
Principal investigator 1 ABBVIE INC. $12,633.60 07/09/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202497590
Principal investigator 1 ABBVIE INC. $2,440.20 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496025
Principal investigator 1 ABBVIE INC. $736.00 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496067
Principal investigator 1 ABBVIE INC. $3,162.60 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496099
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $186.35 06/25/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281830
Principal investigator 1 ABBVIE INC. $2,569.00 06/03/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488287
Principal investigator 1 ABBVIE INC. $736.00 05/21/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202485603
Principal investigator 1 ABBVIE INC. $778.40 05/21/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202485605
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/21/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171802
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/21/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171820
Principal investigator 1 ABBVIE INC. $10,116.40 05/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202482335
Principal investigator 1 ABBVIE INC. $736.00 04/24/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478856
Principal investigator 1 Genentech, Inc. $2,150.00 04/10/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634763
Principal investigator 1 Genentech, Inc. $11,000.00 04/10/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634767
Principal investigator 1 Genentech, Inc. $3,000.00 04/10/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634771
Principal investigator 1 ABBVIE INC. $12,327.00 04/03/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202469405
Principal investigator 1 Janssen Research & Development, LLC $332.00 04/03/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171835
Principal investigator 1 Janssen Research & Development, LLC $228.00 04/03/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171882
Principal investigator 1 SANOFI US SERVICES INC. $8,662.08 03/24/2025 Non-covered Recipient Entity
Om Research Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226122959
Principal investigator 1 PFIZER INC. $1,500.00 03/17/2025 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854036
Principal investigator 1 PFIZER INC. $1,668.00 03/17/2025 Non-covered Recipient Entity
Om Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228854043
Principal investigator 1 ABBVIE INC. $736.00 03/13/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202463050
Principal investigator 1 Genentech, Inc. $2,150.00 03/11/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211634923
Principal investigator 1 Janssen Research & Development, LLC $540.00 02/17/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171826
Principal investigator 1 Janssen Research & Development, LLC $540.00 02/17/2025 Non-covered Recipient Entity
Om Rsrch Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175171858
Principal investigator 1 ABBVIE INC. $736.00 02/13/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202451312
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 02/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 02/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275123
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $725.00 02/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275125
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,950.00 01/10/2025 Non-covered Recipient Entity
Om Research, Llc
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235994966
Principal investigator 1 ABBVIE INC. $2,944.00 01/09/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202437650
Principal investigator 1 ABBVIE INC. $736.00 01/09/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202437654